Načítá se...
Novel Agents Show Promise Against Acquired Endocrine Resistance in ER+ Advanced Breast Cancer
New studies of novel therapies, including giredestrant, H3B‐6545, proxalutamide, and enobosarm, highlight the rich pipeline of future treatment options for patients with advanced, endocrine‐resistant, ER+ breast cancer.
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262303/ https://ncbi.nlm.nih.gov/pubmed/34173302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13874 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|